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Aim: The objective of this study was to investigate whether coenzyme Q10 (CoQ10) supplementation affects M30 and heart-type fatty
acid binding protein (h-FABP) levels in intestinal ischemia–reperfusion injury-induced rats.
Materials and methods: Thirty-two male Wistar rats were randomly divided into 4 groups. 1) Sham: Animals exposed to laparotomy
without clamping the superior mesenteric artery (SMA); 2) ischemia–reperfusion (IR): rats exposed to laparotomy with occlusion of the
SMA for 45 min, followed by 120 min of reperfusion period; 3) CoQ10 plus sham: 10 mg kg body weight–1 CoQ10 was administrated
via intraperitoneal injection for 20 days, and thereafter animals were exposed to laparotomy without clamping the SMA; 4) CoQ10 plus
IR: 10 mg kg body weight–1 CoQ10 was administrated via intraperitoneal injection for 20 days and thereafter animals were exposed to
laparotomy with occlusion of the SMA for 45 min, followed by 120 min of reperfusion period. Blood samples were taken by cardiac
puncture for the analysis of serum h-FABP and M30 levels.
Results: There was no difference among the groups for serum h-FABP and M30 antigen levels.
Conclusion: Neither intestinal ischemia–reperfusion injury nor CoQ10 supplementation affect serum h-FABP and M30 levels in rats.
Key words: Ischemia–reperfusion injury, intestine, coenzyme Q10, M30, h-FABP

1. Introduction
Cessation of the blood supply causes ischemic injury, and
later restoration of the blood supply initiates a cascade of
events that may result in additional cell injury known as
reperfusion injury (1–3). Parks et al. (4) reported that tissue
lesions produced during reperfusion were greater than
those produced during ischemia, in mesenteric ischemia–
reperfusion (IR). Intestinal IR injury is an important
problem in many situations, such as abdominal aortic
aneurysm surgery, cardiopulmonary bypass, strangulated
hernias, neonatal necrotizing enterocolitis, intestinal
transplantation, and hemorrhagic or septic shock (5).
IR of the small intestine can cause the disruption of the
mucosal barrier, bacterial translocation, and the activation
of inflammatory responses, as well as hydroelectrolytic
and acid–alkaline equilibrium disturbances, which are
manifested in distant organs (1). Therefore, intestinal IR
can induce injury to secondary organs such as the liver (6),
heart (7), kidneys (8), and lungs (9).
Fatty acid-binding protein (FABP) is a small (15 kDa)
cytoplasmic protein that is expressed in tissues with an
* Correspondence: mbelviranli@yahoo.com
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active fatty acid metabolism (10). The primary function
of FABP is the facilitation of intracellular long-chain fatty
acid transport (11). The cellular expression of FABPs
is responsive to changes in lipid metabolism as induced
by pathophysiological stimuli like ischemia, endurance
training, and diabetes. Heart-type FABP (h-FABP) is
mainly expressed in cardiomyocytes, but to a lesser extent
also in skeletal muscle, distal tubular cells of the kidney,
specific parts of the brain, lactating mammary glands, and
placenta (10). h-FABP is a sensitive and early marker for
myocardial injury (12).
Cytokeratin 18 (CK18) is a member of the
intermediate filament family of cytoskeletal proteins and
is widely expressed in epithelial and endothelial cells (13).
Cytokeratins are mainly released from tumor cells; they are
also released into the circulation where they may comprise
partly degraded intermediate filament complexes (14).
M30 and M65 antibodies can be used in the detection
of CK18 fragments in the circulation (15). The M30
apoptosense detects a neoepitope specific to apoptosis
caused by caspase cleavage of CK18 at aspartate 396. The
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M65 measures total soluble CK18 (both caspase cleaved
and intact forms), which are released during apoptotic and
nonapoptotic forms of cell death (16).
Coenzyme Q10 (CoQ10) is a lipid soluble endogenous
provitamin naturally found in the mitochondria. CoQ10
carries out 2 major biochemical functions in the cells; the
first is to serve as an electron and proton carrier for energy
coupling and the second is to serve as an antioxidant, acting
as a primary scavenger of free radicals (17,18). Disruption
of the mitochondrial respiratory chain after IR results
in overproduction of reactive oxygen species, opens the
mitochondrial permeability transition pore, and activates
and leaks apoptosis mediators, such as cytochrome c
and caspase 9, out of mitochondria into cytosol. These
proapoptotic factors activate downstream events that
eventually lead to cell apoptosis (19). Numerous studies
have suggested that CoQ10 can scavenge free radicals and
are therefore beneficial against IR injury in several models
of rat IR injury such as the limb (20), brain (21), and liver
(22). CoQ10 may therefore be a logical choice as a therapy
for intestinal ischemia. However, CoQ10 has never been
used as a treatment for intestinal IR injury.
In the present study we hypothesized that since
intestinal IR induces an injury to secondary organs like
the heart, and since recent reports have emphasized the
role of apoptotic cell death in the pathogenesis of IR
injury, intestinal IR may affect M30 and h-FABP levels.
CoQ10 supplementation may have a therapeutic role in
the treatment of intestinal IR injury. Based on the current
reports, the present study was designed to determine the
effect of CoQ10 supplementation on M30 and h-FABP
levels in intestinal IR injury-induced rats.
2. Materials and methods
2.1. Animals
Thirty-two male Wistar rats (aged 16 weeks) weighing
between 300 and 350 g were used in the present study. Rats
were housed in polycarbonate cages and maintained on a
12:12-h light/dark cycle in a temperature (22 ± 2 °C) and
humidity (50%) controlled room. All animals were given
standard rat chow and tap water ad libitum. Animals’
care and all surgical procedures were approved by the
Animal Ethics Committee of the Experimental Medicine
Research and Application Center of Selçuk University.
The experiment was performed in compliance with the
Principles of Laboratory Animal Care formulated by the
National Institute of Health.
2.2. Experimental design
Thirty-two rats were randomly assigned to 4 experimental
groups, 8 rats in each: sham (S), intestinal IR, CoQ10
plus sham (CoQ10+S) and CoQ10 plus intestinal IR
(CoQ10+IR). The rats in sham groups underwent
laparotomy only, without superior mesenteric artery

(SMA) occlusion. The rats in intestinal IR groups
underwent a laparotomy and intestinal IR. The rats in
CoQ10 groups received a pretreatment by intraperitoneal
injection with CoQ10 at 10 mg kg body weight–1 for 20
days before operation.
2.3. CoQ10 treatment and surgical procedures
Rats were fasted for 12 h with free access to water before
operation. The CoQ10 supplemented groups (CoQ10+S,
CoQ10+IR) received an intraperitoneal administration
of CoQ10 (C9538, Sigma Chemical Co., St. Louis,
MO, USA) at doses of 10 mg kg body weight–1 per day
dissolved in corn oil (C8267, Sigma Chemical Co.) for
20 days before the operation. The rats were anesthetized
by intramuscular injection of ketamine hydrochloride
(50 mg kg body weight–1) and xylazine (10 mg kg body
weight–1). The abdomen was opened with a midline
incision. Intestines were exteriorized and the SMA was
dissected. After identifying the SMA, the small intestine
was subjected to ischemia by occluding the SMA with a
nontraumatic microvascular clamp. Adequate occlusion
was confirmed by pallor and the absence of pulsation in
the mesenteric vessels of the small intestine. The clamp
was removed 45 min later and reperfusion was provided
for 120 min. Reperfusion was confirmed by the restoration
of pulsation and color prior to closing the incision. During
the reperfusion phase, the abdominal cavity was closed
with sutures. In the present study, we chose a model of 45min occlusion of the SMA because the effectiveness of this
duration was demonstrated in a previous study (2). Rats in
the sham group were exposed to the abdominal incision
but not the intestinal IR. After the reperfusion state, blood
samples were taken by cardiac puncture and the rats were
sacrificed by cervical dislocation.
2.4. Biochemical analysis
Blood samples were transferred into tubes containing
no additive and allowed to clot at room temperature for
30 min, and then serum was separated by centrifugation
at 3000 rpm for 15 min. Serum aliquots were stored at
–80 °C immediately until analysis. Serum h-FABP levels
were measured by enzyme-linked immunosorbent assay
(ELISA) with a commercially available kit (Cusabio
Biotech Co., Ltd., Newark, DE, USA). Briefly, standards
or samples were added to the precoated plate with an
antibody specific to h-FABP, and avidin conjugated to
horseradish peroxidase was added to each microplate well
and incubated. A 3,3’,5,5’-tetramethyl-benzidine substrate
solution was then added to each well. The enzyme–
substrate reaction was terminated by the addition of a
sulfuric acid solution and the color change was measured
spectrophotometrically at a wavelength of 450 nm. h-FABP
levels were expressed as ng mL–1. Serum levels of M30
antigen were determined with a commercially available
ELISA kit (Peviva AB, Bromma, Sweden) according to the
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manufacturer’s instructions. M30-Apoptosense ELISA is
based on the M30 monoclonal antibody, which specifically
recognizes a neoepitope formed after cleavage of CK18, a
process specifically occurring during apoptosis of CK18containing cells. Briefly, samples were placed into wells
coated with a monoclonal antibody as a catcher. After
washing, a horseradish peroxidase-conjugated antibody
was used for detection. Reference concentrations of
M30 antigen were used to prepare assay calibration. The
absorbance was determined with an ELISA reader at 450
nm. M30 levels were expressed as U L–1.
2.5. Statistical analysis
Statistical analyses were carried out using SPSS for
Windows, version 15.0. Data were presented as mean
± standard deviation (SD) and median (min-max) for
normally distributed and not normally distributed
variables, respectively. Data within groups were initially
analyzed using the Shapiro–Wilk test for normality. For

normally distributed variables (M30), Levene’s test was
used to test whether variances among the groups were
homogeneous. If Levene’s test indicated homogeneous
variances, the groups were compared by one-way analysis
of variance for equal variances. h-FABP levels that
were not normally distributed were analyzed with the
nonparametric Kruskal–Wallis test. The Mann–Whitney
test was used for paired comparisons. P < 0.05 was
considered statistically significant.
3. Results
Serum h-FABP levels of the groups are demonstrated in
the Table. There was no statistically significant difference
among the groups (P > 0.05) (Figure 1).
Serum M30 levels of the study groups are demonstrated
in Figure 2. M30 levels were not different among the
groups (S: 196.53 ± 45.84 U L–1, IR: 229.20 ± 96.03 U L–1,
CoQ10+S: 181.27 ± 58.31 U L–1, CoQ10+IR: 202.64 ±
48.58 U L–1).

Groups

n

h-FABP (ng mL–1)

S

8

0.2696 (0.08–3.36)

IR

8

0.0800 (0.08–1.92)

CoQ10+S

8

0.0800 (0.08–0.90)

CoQ10+IR

8

0.0800 (0.08–0.21)

250

0.30

200

0.25

150

(M30 levels (U L–1)

h-FABP levels (ng mL–1)

Table. Effects of intestinal IR and CoQ10 supplementation on serum h-FABP levels.
Data are expressed as medians (minimum-maximum). S: Sham, IR: ischemia–
reperfusion, CoQ10+S: coenzyme Q10 plus sham, CoQ10+IR: coenzyme Q10 plus
ischemia–reperfusion.

100
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0

S
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CoQ10+S CoQ10+IR

Figure 1. Effects of intestinal IR and CoQ10 supplementation on
serum h-FABP levels. Data are expressed as medians. S: Sham,
IR: ischemia–reperfusion, CoQ10+S: coenzyme Q10 plus sham,
CoQ10+IR: coenzyme Q10 plus ischemia–reperfusion.
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Figure 2. Effects of intestinal IR and CoQ10 supplementation on
serum M30 levels. S: Sham, IR: ischemia–reperfusion, CoQ10+S:
coenzyme Q10 plus sham, CoQ10+IR: coenzyme Q10 plus
ischemia–reperfusion.
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4. Discussion
This study is the first to evaluate the effect of CoQ10
supplementation on M30 and h-FABP levels in
intestinal IR injury-induced rats. The evidence from
this study indicates that neither intestinal IR nor CoQ10
supplementation affected serum M30 and h-FABP levels
in rats. This study provides a new insight into intestinal IR
injury. We demonstrated that 45 min of intestinal ischemia
with 120 min of reperfusion may not affect intestinal
barrier integrity and epithelial lining.
In the present study, serum h-FABP levels were not
affected by intestinal IR and CoQ10 supplementation.
In previous studies (7,23), a marked deficit of cardiac
performance with dysfunction in myocardial contraction
and relaxation was reported as a consequence of
intestinal IR in experimental animals. Horton and White
(23) demonstrated that one of the mechanisms that
promote cardiac dysfunction after intestinal IR in rats
is the production of ROS in cardiac cell membranes.
It has been shown that although cardiac high-energy
phosphate levels are preserved during experimental
intestinal IR injury, fatty acid oxidation is impaired (24).
As fatty acids are the preferred fuel of the heart, altered
substrate selection and reliance on alternative fuels could
lead to cardiac impairment (25). However, there is no
report evaluating the effects of intestinal IR on h-FABP
levels. Based on the current findings, we suggest that our
ischemia period was too short to elevate h-FABP levels in
the circulation. It has been suggested that when intestinal
ischemia is limited to a period of less than 2 h, only the
villi are affected while the crypt cells remain intact, and
there is a rapid recovery of function (26). In the current
study we applied 45 min of ischemia and this duration
was not sufficient to affect h-FABP levels. Since intestinal
and liver fatty acid-binding proteins are mainly expressed
in the villi and not in the crypt, both proteins may be
early and sensitive plasma markers of intestinal ischemia
(10). Previous studies (27,28) described the applicability
of intestinal fatty acid-binding protein for the detection
of rat intestinal injury. In the present study, since we
investigated distant organ damage, we measured h-FABP
levels. h-FABP is more specific for heart muscle than
other types of fatty acid-binding protein (29) and it is
an early marker of myocardial injury (12). Additionally,
CoQ10 supplementation did not affect h-FABP levels
in intestinal IR induced or sham-operated rats. To our
knowledge, no study to date has investigated the effects
of CoQ10 on h-FABP levels. However, in previous
reports the effects of CoQ10 supplementation were
investigated in many different IR models, such as hepatic
(22), urinary bladder (30), and limb (20) ischemia, and
in those studies the protective effect of CoQ10 against

IR-induced oxidative stress was demonstrated. In the
present study, these findings suggest that mechanisms
other than oxidative stress may affect h-FABP levels.
Therefore, CoQ10 supplementation may not affect
h-FABP levels.
In the present study, neither intestinal IR nor CoQ10
supplementation affected serum M30 levels. In many studies
(15,31,32) it has been demonstrated that serum M30 levels
increased in several types of cancers, and it has been also
found that M30 levels were correlated with tumor volume
(33). Previous reports (34,35) have suggested the role of
apoptotic cell death in the pathogenesis of IR injury. Apart
from necrotic cell death, immunohistochemistry for M30
revealed that apoptotic cell death occurred particularly
during reperfusion (36). In the study by Grootjans et al. (36),
M30 arteriovenous concentration differences remained
low during reperfusion, suggesting that M30 remained
within the apoptotic bodies and was not released into the
circulation. In addition, leaking M30 (from apoptotically
dying enterocytes undergoing secondary necrosis) was
minimally exposed to lamina propria vasculature, because
M30-positive cells were mainly detected in the detached
enterocytes, thereby limiting release into the circulation
(36). Based on this current information, unchanged M30
levels might be related to the duration of ischemia. As we
mentioned above, in intestinal ischemia that is limited to
a period of less than 2 h, only the villi are affected while
the crypt cells remain intact. In a study by Topaloglu et al.
(35), it was suggested that hepatocyte apoptosis may play a
role in the development of IR injury of the liver. In another
study, Ulukaya et al. (37) showed that CK18 seems to be
useful to discriminate and quantitate the type of cell death
during early ischemia and reperfusion periods of liver
transplantation. Additionally, CoQ10 supplementation
did not affect serum M30 levels in intestinal IR induced or
sham-operated rats. To our knowledge, there is no report
to date demonstrating the effects of CoQ10 on M30 levels.
Therefore, we suggest that CoQ10 supplementation may
not affect M30 levels in intestinal IR-induced or shamoperated rats.
In conclusion, the results of the present study suggest
that intestinal ischemia–reperfusion injury with a short
ischemic period and/or coenzyme Q10 supplementation
does not affect serum h-FABP and M30 levels in rats.
However, further and detailed studies are needed in this
area to clarify the mechanism of action, the alterations that
occur during the intestinal ischemia–reperfusion, and the
role of coenzyme Q10 in this process.
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